146 related articles for article (PubMed ID: 36807558)
1. Impact of elexacaftor/tezacaftor/ivacaftor on bacterial cultures from people with cystic fibrosis.
Beck MR; Hornick DB; Pena TA; Singh SB; Wright BA
Pediatr Pulmonol; 2023 May; 58(5):1569-1573. PubMed ID: 36807558
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor.
Reasoner SA; Bernard R; Waalkes A; Penewit K; Lewis J; Sokolow AG; Brown RF; Edwards KM; Salipante SJ; Hadjifrangiskou M; Nicholson MR
mBio; 2024 Feb; 15(2):e0193523. PubMed ID: 38275294
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for
Mall MA; Brugha R; Gartner S; Legg J; Moeller A; Mondejar-Lopez P; Prais D; Pressler T; Ratjen F; Reix P; Robinson PD; Selvadurai H; Stehling F; Ahluwalia N; Arteaga-Solis E; Bruinsma BG; Jennings M; Moskowitz SM; Noel S; Tian S; Weinstock TG; Wu P; Wainwright CE; Davies JC
Am J Respir Crit Care Med; 2022 Dec; 206(11):1361-1369. PubMed ID: 35816621
[No Abstract] [Full Text] [Related]
4. Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One
Wainwright C; McColley SA; McNally P; Powers M; Ratjen F; Rayment JH; Retsch-Bogart G; Roesch E; Ahluwalia N; Chin A; Chu C; Lu M; Menon P; Waltz D; Weinstock T; Zelazoski L; Davies JC
Am J Respir Crit Care Med; 2023 Jul; 208(1):68-78. PubMed ID: 37154609
[No Abstract] [Full Text] [Related]
5. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two
Graeber SY; Vitzthum C; Pallenberg ST; Naehrlich L; Stahl M; Rohrbach A; Drescher M; Minso R; Ringshausen FC; Rueckes-Nilges C; Klajda J; Berges J; Yu Y; Scheuermann H; Hirtz S; Sommerburg O; Dittrich AM; Tümmler B; Mall MA
Am J Respir Crit Care Med; 2022 Mar; 205(5):540-549. PubMed ID: 34936849
[No Abstract] [Full Text] [Related]
6. Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study.
Bower JK; Volkova N; Ahluwalia N; Sahota G; Xuan F; Chin A; Weinstock TG; Ostrenga J; Elbert A
J Cyst Fibros; 2023 Jul; 22(4):730-737. PubMed ID: 36963986
[TBL] [Abstract][Full Text] [Related]
7. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two
Graeber SY; Renz DM; Stahl M; Pallenberg ST; Sommerburg O; Naehrlich L; Berges J; Dohna M; Ringshausen FC; Doellinger F; Vitzthum C; Röhmel J; Allomba C; Hämmerling S; Barth S; Rückes-Nilges C; Wielpütz MO; Hansen G; Vogel-Claussen J; Tümmler B; Mall MA; Dittrich AM
Am J Respir Crit Care Med; 2022 Aug; 206(3):311-320. PubMed ID: 35536314
[No Abstract] [Full Text] [Related]
8. Elexacaftor/tezacaftor/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del.
Lopez A; Daly C; Vega-Hernandez G; MacGregor G; Rubin JL
J Cyst Fibros; 2023 Jul; 22(4):607-614. PubMed ID: 36849331
[TBL] [Abstract][Full Text] [Related]
9. Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events.
Ramsey B; Correll CU; DeMaso DR; McKone E; Tullis E; Taylor-Cousar JL; Chu C; Volkova N; Ahluwalia N; Waltz D; Tian S; Mall MA
Am J Respir Crit Care Med; 2024 Feb; 209(3):299-306. PubMed ID: 37890129
[No Abstract] [Full Text] [Related]
10. The use of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis postliver transplant: A case series.
Ragan H; Autry E; Bomersback T; Hewlett J; Kormelink L; Safirstein J; Shanley L; Lubsch L
Pediatr Pulmonol; 2022 Feb; 57(2):411-417. PubMed ID: 34850610
[TBL] [Abstract][Full Text] [Related]
11. EFFECT OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR ON ANNUAL RATE OF LUNG FUNCTION DECLINE IN PEOPLE WITH CYSTIC FIBROSIS.
Lee T; Sawicki GS; Altenburg J; Millar SJ; Geiger JM; Jennings MT; Lou Y; McGarry LJ; Van Brunt K; Linnemann RW
J Cyst Fibros; 2023 May; 22(3):402-406. PubMed ID: 36581485
[TBL] [Abstract][Full Text] [Related]
12. Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients.
Doligalski CT; McKinzie CJ; Yang A; Lobo LJ; Coakley R
Pharmacotherapy; 2022 Jul; 42(7):580-584. PubMed ID: 35689451
[TBL] [Abstract][Full Text] [Related]
13. Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation.
Sadras I; Kerem E; Livnat G; Sarouk I; Breuer O; Reiter J; Gileles-Hillel A; Inbar O; Cohen M; Gamliel A; Stanleigh N; Gunawardena T; Bartlett C; Gonska T; Moraes T; Eckford PDW; Bear CE; Ratjen F; Kerem B; Wilschanski M; Shteinberg M; Cohen-Cymberknoh M
J Cyst Fibros; 2023 Nov; 22(6):1062-1069. PubMed ID: 37331863
[TBL] [Abstract][Full Text] [Related]
14. Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosis.
Marshall LZ; Espinosa R; Starner CI; Gleason PP
J Manag Care Spec Pharm; 2023 Jun; 29(6):599-606. PubMed ID: 37276039
[No Abstract] [Full Text] [Related]
15. A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation.
McKone EF; DiMango EA; Sutharsan S; Barto TL; Campbell D; Ahluwalia N; Higgins M; Owen CA; Tullis E
J Cyst Fibros; 2021 Mar; 20(2):234-242. PubMed ID: 33339768
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one
Daines CL; Tullis E; Costa S; Linnemann RW; Mall MA; McKone EF; Polineni D; Quon BS; Ringshausen FC; Rowe SM; Selvadurai H; Taylor-Cousar JL; Withers NJ; Ahluwalia N; Moskowitz SM; Prieto-Centurion V; Tan YV; Tian S; Weinstock T; Xuan F; Zhang Y; Ramsey B; Griese M;
Eur Respir J; 2023 Dec; 62(6):. PubMed ID: 37945033
[TBL] [Abstract][Full Text] [Related]
17. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Healthcare Resource Utilization and Associated Costs Among People With Cystic Fibrosis in the US: A Retrospective Claims Analysis.
Schechter MS; Sabater-Anaya N; Oster G; Weycker D; Wu H; Arteaga-Solis E; Bagal S; McGarry LJ; Van Brunt K; Geiger JM
Pulm Ther; 2023 Dec; 9(4):479-498. PubMed ID: 37874528
[TBL] [Abstract][Full Text] [Related]
18. The Rapid Reduction of Infection-Related Visits and Antibiotic Use Among People With Cystic Fibrosis After Starting Elexacaftor-Tezacaftor-Ivacaftor.
Miller AC; Harris LM; Cavanaugh JE; Abou Alaiwa M; Stoltz DA; Hornick DB; Polgreen PM
Clin Infect Dis; 2022 Sep; 75(7):1115-1122. PubMed ID: 35142340
[TBL] [Abstract][Full Text] [Related]
19. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One
Zemanick ET; Taylor-Cousar JL; Davies J; Gibson RL; Mall MA; McKone EF; McNally P; Ramsey BW; Rayment JH; Rowe SM; Tullis E; Ahluwalia N; Chu C; Ho T; Moskowitz SM; Noel S; Tian S; Waltz D; Weinstock TG; Xuan F; Wainwright CE; McColley SA
Am J Respir Crit Care Med; 2021 Jun; 203(12):1522-1532. PubMed ID: 33734030
[No Abstract] [Full Text] [Related]
20. Effects of elexacaftor/tezacaftor/ivacaftor therapy in children with cystic fibrosis - a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI.
Streibel C; Willers CC; Pusterla O; Bauman G; Stranzinger E; Brabandt B; Bieri O; Curdy M; Bullo M; Frauchiger BS; Korten I; Krüger L; Casaulta C; Ratjen F; Latzin P; Kieninger E
J Cyst Fibros; 2023 Jul; 22(4):615-622. PubMed ID: 36635199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
